News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

iBio, Inc. (IBPM) Announces Rights Grant for Anthrax-Plague Combination Vaccine To Fraunhofer USA Center for Molecular Biotechnology



4/7/2010 8:50:41 AM

NEWARK, Del.--(BUSINESS WIRE)--iBio, Inc. (OTCBB: IBPM) confirmed today the grant of rights to use iBio’s proprietary technology, the iBioLaunch™ platform, in support of a $5.3 million government-funded project for the development of a single vaccine to protect against both anthrax and plague. The project will be managed by Fraunhofer USA Center for Molecular Biotechnology (CMB) pursuant to the long-term agreement between iBio and CMB for advancement of the iBio technology.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES